Evotec AG (ETR:EVT) received a €13.00 ($14.61) price target from equities researchers at Berenberg Bank in a report issued on Tuesday. The firm presently has a “neutral” rating on the stock.

Evotec AG (ETR EVT) traded up 3.13% during mid-day trading on Tuesday, reaching €13.49. 35,812 shares of the company’s stock traded hands. Evotec AG has a 1-year low of €3.30 and a 1-year high of €13.60. The firm has a market cap of €1.88 billion and a PE ratio of 53.32. The firm has a 50 day moving average of €11.97 and a 200 day moving average of €8.75.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/06/11/berenberg-bank-analysts-give-evotec-ag-evt-a-13-00-price-target.html.

Evotec AG Company Profile

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.